FY2027 EPS Estimates for Doximity Raised by Leerink Partnrs

Doximity, Inc. (NASDAQ:DOCS) – Stock analysts at Leerink Partnrs raised their FY2027 EPS estimates for Doximity in a research note issued on Monday, March 3rd. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $1.33 per share for the year, up from their prior forecast of $1.31. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Doximity’s current full-year earnings is $0.99 per share. Leerink Partnrs also issued estimates for Doximity’s FY2028 earnings at $1.47 EPS.

A number of other brokerages also recently issued reports on DOCS. Leerink Partners raised Doximity from a “market perform” rating to an “outperform” rating and upped their price target for the company from $60.00 to $90.00 in a report on Friday, February 7th. Canaccord Genuity Group upped their price target on Doximity from $60.00 to $71.00 and gave the company a “hold” rating in a report on Friday, February 7th. Barclays upped their price target on Doximity from $52.00 to $75.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Stephens began coverage on Doximity in a report on Friday, December 20th. They issued an “equal weight” rating and a $55.00 price target for the company. Finally, Needham & Company LLC upped their price target on Doximity from $65.00 to $82.00 and gave the company a “buy” rating in a report on Friday, February 7th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $64.22.

Doximity Stock Performance

Shares of Doximity stock opened at $67.78 on Tuesday. Doximity has a one year low of $22.96 and a one year high of $85.21. The company has a market cap of $12.65 billion, a PE ratio of 67.78, a P/E/G ratio of 4.10 and a beta of 1.39. The business has a 50-day simple moving average of $62.30 and a 200-day simple moving average of $51.18.

Insider Transactions at Doximity

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the completion of the transaction, the director now owns 6,360 shares in the company, valued at approximately $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 37.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Global Retirement Partners LLC grew its holdings in Doximity by 468.1% in the fourth quarter. Global Retirement Partners LLC now owns 534 shares of the company’s stock valued at $29,000 after purchasing an additional 440 shares during the last quarter. UMB Bank n.a. grew its holdings in Doximity by 69.1% in the fourth quarter. UMB Bank n.a. now owns 575 shares of the company’s stock valued at $31,000 after purchasing an additional 235 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Doximity by 324.2% in the third quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock valued at $34,000 after purchasing an additional 603 shares during the last quarter. Larson Financial Group LLC grew its holdings in Doximity by 49.4% in the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock valued at $40,000 after purchasing an additional 250 shares during the last quarter. Finally, Optimum Investment Advisors acquired a new stake in Doximity in the fourth quarter valued at $43,000. Hedge funds and other institutional investors own 87.19% of the company’s stock.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.